Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Florbetaben F18 - Piramal

Drug Profile

Florbetaben F18 - Piramal

Alternative Names: 18F-AV 1; 18F-AV1/ZK; [18F] florbetaben; AV-1; AV-1/ZK; BAY 94-9172; Florbetaben 18F; NeuraCeq; UNII-TLA7312TOI; ZK 6013443

Latest Information Update: 05 Apr 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Avid Radiopharmaceuticals
  • Developer Avid Radiopharmaceuticals; Bayer HealthCare Pharmaceuticals; Ci-Co Healthcare; Isologic Innovative Radiopharmaceuticals; PET Pharm Biotech; Piramal Enterprises
  • Class Aniline compounds; Radiopharmaceutical diagnostics; Small molecules
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Alzheimer's disease
  • No development reported Mild cognitive impairment

Most Recent Events

  • 28 Dec 2018 Keio University School of Medicine completes the clinical trial in Alzheimer's disease (Diagnosis, In volunteers) in Japan (UMIN000025420)
  • 01 Aug 2018 Fundacion Clinic per a la Recerca Biomédica plans a phase II trial for Cognition-disorders (Prevention) presumably in Spain (NCT03057938)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Mild-cognitive-impairment(Diagnosis) in Australia (IV, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top